Related Experiment Video
Updated: Sep 11, 2025
Diagonal Method to Measure Synergy Among Any Number of Drugs
Published on: June 21, 2018
SynProtX: a large-scale proteomics-based deep learning model for predicting synergistic anticancer drug combinations
Bundit Boonyarit1, Matin Kositchutima2, Tisorn Na Phattalung2
1School of Information Science and Technology, Vidyasirimedhi Institute of Science and Technology, Rayong 21210, Thailand.
Motivation:
Drug combination therapy plays a pivotal role in addressing the molecular heterogeneity of cancer, improving treatment efficacy, minimizing resistance, and reducing toxicity. Deep learning approaches have significantly advanced drug combination discovery by addressing the limitations of conventional laboratory experiments, which are time-consuming and costly. While most existing models rely on the molecular structure of drugs and gene expression data, incorporating protein-level expression provides a more accurate representation of cellular behavior and drug responses. In this study, we introduce SynProtX, an enhanced deep learning model that explicitly integrates large-scale proteomics with deep neural networks (DNNs) and the molecular structure of drugs with graph neural networks (GNNs).
Results:
The SynProtX-GATFP model, which combines molecular graphs and fingerprints through a graph attention network architecture, demonstrated superior predictive performance for the FRIEDMAN study dataset. We further evaluated its cell line-specific performance, which achieved accuracy across diverse tissue and study datasets. By incorporating protein expression data, the model consistently enhanced predictive performance over gene expression-only models, reflecting the functional state of cancer cells. The generalizability of SynProtX was rigorously validated using cold-start prediction, including leave-drug-combination-out, leave-drug-out, and leave-cell-line-out validation strategies, highlighting its robust performance and potential for clinical applicability. Additionally, SynProtX identified key cancer-associated proteins and molecular substructures, offering novel insights into the biological mechanisms underlying drug synergy. These findings highlight the potential of integrating large-scale proteomics and multiomics data to advance anticancer drug design and combination therapy strategies for personalized medicine. Availability and implementation: https://github.com/manbaritone/SynProtX.
Insights
This study introduces SynProtX, a deep learning model that integrates protein expression data with drug structures to improve cancer drug combination discovery. The model shows enhanced predictive performance, offering insights into drug synergy and personalized medicine strategies.
Area of Science:
- Computational Biology
- Drug Discovery
- Oncology
Background:
- Drug combination therapy is crucial for overcoming cancer's molecular heterogeneity and improving treatment outcomes.
- Deep learning models accelerate drug combination discovery, overcoming limitations of traditional experimental methods.
- Integrating protein-level expression data offers a more accurate cellular behavior and drug response representation than gene expression alone.
Purpose of the Study:
- Introduce SynProtX, a deep learning model that integrates large-scale proteomics with deep neural networks (DNNs) and drug molecular structures with graph neural networks (GNNs).
- Enhance the accuracy and efficiency of predicting effective anticancer drug combinations.
- Provide a framework for personalized medicine by leveraging multiomics data.
Main Methods:
- Developed SynProtX, a model combining graph neural networks (GNNs) for drug molecular structures and deep neural networks (DNNs) for proteomics data.
- Utilized graph attention network architecture (SynProtX-GATFP) to integrate molecular graphs and fingerprints.
- Employed rigorous validation strategies including cold-start prediction (leave-drug-combination-out, leave-drug-out, leave-cell-line-out).
Main Results:
- SynProtX-GATFP demonstrated superior predictive performance on the FRIEDMAN dataset and achieved high accuracy across diverse cell lines and datasets.
- Incorporating protein expression data consistently improved predictive performance compared to gene expression-only models.
- The model successfully identified key cancer-associated proteins and molecular substructures, revealing mechanisms of drug synergy.
Conclusions:
- SynProtX effectively integrates proteomics and drug structure data for enhanced anticancer drug combination prediction.
- The model's robust validation and identification of synergistic mechanisms highlight its potential for clinical applicability and personalized medicine.
- Leveraging large-scale proteomics and multiomics data is a promising avenue for advancing anticancer drug design.
More Related Videos
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
07:51High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
Published on: May 21, 2018
Related Concept Videos
01:27Combined Effects of Drugs: Synergism
Such synergistic combinations...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...